Cargando…
A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural pro...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470589/ https://www.ncbi.nlm.nih.gov/pubmed/37338298 http://dx.doi.org/10.1128/mbio.01060-23 |
_version_ | 1785099712573997056 |
---|---|
author | Grimes, Samantha L. Choi, Young J. Banerjee, Anoosha Small, Gabriel Anderson-Daniels, Jordan Gribble, Jennifer Pruijssers, Andrea J. Agostini, Maria L. Abu-Shmais, Alexandra Lu, Xiaotao Darst, Seth A. Campbell, Elizabeth Denison, Mark R. |
author_facet | Grimes, Samantha L. Choi, Young J. Banerjee, Anoosha Small, Gabriel Anderson-Daniels, Jordan Gribble, Jennifer Pruijssers, Andrea J. Agostini, Maria L. Abu-Shmais, Alexandra Lu, Xiaotao Darst, Seth A. Campbell, Elizabeth Denison, Mark R. |
author_sort | Grimes, Samantha L. |
collection | PubMed |
description | Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural protein 12 RNA-dependent RNA polymerase (nsp12-RdRp). We here show that a substitution mutation in the nsp13-helicase (nsp13-HEL A335V) of the betacoronavirus murine hepatitis virus (MHV) that was selected during passage with the RDV parent compound confers partial RDV resistance independently and additively when expressed with co-selected RDV resistance mutations in the nsp12-RdRp. The MHV A335V substitution did not enhance replication or competitive fitness compared to WT MHV and remained sensitive to the active form of the cytidine nucleoside analog antiviral molnupiravir (MOV). Biochemical analysis of the SARS-CoV-2 helicase encoding the homologous substitution (A336V) demonstrates that the mutant protein retained the ability to associate with the core replication proteins nsps 7, 8, and 12 but had impaired helicase unwinding and ATPase activity. Together, these data identify a novel determinant of nsp13-HEL enzymatic activity, define a new genetic pathway for RDV resistance, and demonstrate the importance of surveillance for and testing of helicase mutations that arise in SARS-CoV-2 genomes. IMPORTANCE: Despite the development of effective vaccines against COVID-19, the continued circulation and emergence of new variants support the need for antivirals such as RDV. Understanding pathways of antiviral resistance is essential for surveillance of emerging variants, development of combination therapies, and for identifying potential new targets for viral inhibition. We here show a novel RDV resistance mutation in the CoV helicase also impairs helicase functions, supporting the importance of studying the individual and cooperative functions of the replicase nonstructural proteins 7–16 during CoV RNA synthesis. The homologous nsp13-HEL mutation (A336V) has been reported in the GISAID database of SARS-CoV-2 genomes, highlighting the importance of surveillance of and genetic testing for nucleoside analog resistance in the helicase. |
format | Online Article Text |
id | pubmed-10470589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-104705892023-09-01 A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance Grimes, Samantha L. Choi, Young J. Banerjee, Anoosha Small, Gabriel Anderson-Daniels, Jordan Gribble, Jennifer Pruijssers, Andrea J. Agostini, Maria L. Abu-Shmais, Alexandra Lu, Xiaotao Darst, Seth A. Campbell, Elizabeth Denison, Mark R. mBio Research Article Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural protein 12 RNA-dependent RNA polymerase (nsp12-RdRp). We here show that a substitution mutation in the nsp13-helicase (nsp13-HEL A335V) of the betacoronavirus murine hepatitis virus (MHV) that was selected during passage with the RDV parent compound confers partial RDV resistance independently and additively when expressed with co-selected RDV resistance mutations in the nsp12-RdRp. The MHV A335V substitution did not enhance replication or competitive fitness compared to WT MHV and remained sensitive to the active form of the cytidine nucleoside analog antiviral molnupiravir (MOV). Biochemical analysis of the SARS-CoV-2 helicase encoding the homologous substitution (A336V) demonstrates that the mutant protein retained the ability to associate with the core replication proteins nsps 7, 8, and 12 but had impaired helicase unwinding and ATPase activity. Together, these data identify a novel determinant of nsp13-HEL enzymatic activity, define a new genetic pathway for RDV resistance, and demonstrate the importance of surveillance for and testing of helicase mutations that arise in SARS-CoV-2 genomes. IMPORTANCE: Despite the development of effective vaccines against COVID-19, the continued circulation and emergence of new variants support the need for antivirals such as RDV. Understanding pathways of antiviral resistance is essential for surveillance of emerging variants, development of combination therapies, and for identifying potential new targets for viral inhibition. We here show a novel RDV resistance mutation in the CoV helicase also impairs helicase functions, supporting the importance of studying the individual and cooperative functions of the replicase nonstructural proteins 7–16 during CoV RNA synthesis. The homologous nsp13-HEL mutation (A336V) has been reported in the GISAID database of SARS-CoV-2 genomes, highlighting the importance of surveillance of and genetic testing for nucleoside analog resistance in the helicase. American Society for Microbiology 2023-06-20 /pmc/articles/PMC10470589/ /pubmed/37338298 http://dx.doi.org/10.1128/mbio.01060-23 Text en Copyright © 2023 Grimes et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Grimes, Samantha L. Choi, Young J. Banerjee, Anoosha Small, Gabriel Anderson-Daniels, Jordan Gribble, Jennifer Pruijssers, Andrea J. Agostini, Maria L. Abu-Shmais, Alexandra Lu, Xiaotao Darst, Seth A. Campbell, Elizabeth Denison, Mark R. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
title | A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
title_full | A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
title_fullStr | A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
title_full_unstemmed | A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
title_short | A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
title_sort | mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470589/ https://www.ncbi.nlm.nih.gov/pubmed/37338298 http://dx.doi.org/10.1128/mbio.01060-23 |
work_keys_str_mv | AT grimessamanthal amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT choiyoungj amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT banerjeeanoosha amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT smallgabriel amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT andersondanielsjordan amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT gribblejennifer amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT pruijssersandreaj amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT agostinimarial amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT abushmaisalexandra amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT luxiaotao amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT darstsetha amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT campbellelizabeth amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT denisonmarkr amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT grimessamanthal mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT choiyoungj mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT banerjeeanoosha mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT smallgabriel mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT andersondanielsjordan mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT gribblejennifer mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT pruijssersandreaj mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT agostinimarial mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT abushmaisalexandra mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT luxiaotao mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT darstsetha mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT campbellelizabeth mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance AT denisonmarkr mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance |